|
1
|
Chng WJ, Dispenzieri A, Chim CS, Fonseca
R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS,
Sonneveld P, et al: IMWG consensus on risk stratification in
multiple myeloma. Leukemia. 28:269–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jelinek T, Kryukov F, Rihova L and Hajek
R: Plasma cell leukemia: From biology to treatment. Eur J Haematol.
95:16–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mosca L, Musto P, Todoerti K, Barbieri M,
Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM,
et al: Genome-wide analysis of primary plasma cell leukemia
identifies recurrent imbalances associated with changes in
transcriptional profiles. Am J Hematol. 88:16–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lovec H, Grzeschiczek A, Kowalski MB and
Möröy T: Cyclin D1/bcl-1 cooperates with myc genes in the
generation of B-cell lymphoma in transgenic mice. EMBO J.
13:3487–3495. 1994.PubMed/NCBI
|
|
5
|
Shaffer LG, Slovak ML and Campbell LJ: An
International System for Human Cytogenetic Nomenclature (2009).
Karger. Basel: 2009.
|
|
6
|
Sykes PJ, Neoh SH, Brisco MJ, Hughes E,
Condon J and Morley AA: Quantitation of targets for PCR by use of
limiting dilution. Biotechniques. 13:444–449. 1992.PubMed/NCBI
|
|
7
|
Lichter P, Tang Chang CJ, Call K,
Hermanson G, Evans GA, Housman D and Ward DC: High-resolution
mapping of human chromosome 11 by in situ hybridization with cosmid
clones. Science. 247:64–69. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arcaini L, Zibellini S, Boveri E, Riboni
R, Rattotti S, Varettoni M, Guerrera ML, Lucioni M, Tenore A, Merli
M, et al: The BRAF V600E mutation in hairy cell leukemia and other
mature B-cell neoplasms. Blood. 119:188–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Janssen JW, Vaandrager JW, Heuser T, Jauch
A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki
T, et al: Concurrent activation of a novel putative transforming
gene, myeov, and cyclin D1 in a subset of multiple myeloma cell
lines with t(11;14)(q13;q32). Blood. 95:2691–2698. 2000.PubMed/NCBI
|
|
10
|
Specht K, Haralambieva E, Bink K, Kremer
M, Mandl-Weber S, Koch I, Tomer R, Hofler H, Schuuring E, Kluin PM,
et al: Different mechanisms of cyclin D1 overexpression in multiple
myeloma revealed by fluorescence in situ hybridization and
quantitative analysis of mRNA levels. Blood. 104:1120–1126. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moreaux J, Hose D, Bonnefond A, Reme T,
Robert N, Goldschmidt H and Klein B: MYEOV is a prognostic factor
in multiple myeloma. Exp Hematol. 38:1189.e3–1198.e3. 2010.
View Article : Google Scholar
|
|
12
|
Carneiro A, Isinger A, Karlsson A,
Johansson J, Jönsson G, Bendahl PO, Falkenback D, Halvarsson B and
Nilbert M: Prognostic impact of array-based genomic profiles in
esophageal squamous cell cancer. BMC Cancer. 8:982008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lawlor G, Doran PP, MacMathuna P and
Murray DW: MYEOV (myeloma overexpressed gene) drives colon cancer
cell migration and is regulated by PGE2. J Exp Clin Cancer Res.
29:812010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian E, Sawyer JR, Heuck CJ, Zhang Q, van
Rhee F, Barlogie B and Epstein J: In multiple myeloma, 14q32
translocations are nonrandom chromosomal fusions driving high
expression levels of the respective partner genes. Genes
Chromosomes Cancer. 53:549–557. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chapman MA, Lawrence MS, Keats JJ,
Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann
GJ, Adli M, et al: Initial genome sequencing and analysis of
multiple myeloma. Nature. 471:467–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Andrulis M, Lehners N, Capper D, Penzel R,
Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho
AD, et al: Targeting the BRAF V600E mutation in multiple myeloma.
Cancer Discov. 3:862–869. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bohn OL, Hsu K, Hyman DM, Pignataro DS,
Giralt S and Teruya-Feldstein J: BRAF V600E mutation and clonal
evolution in a patient with relapsed refractory myeloma with
plasmablastic differentiation. Clin Lymphoma Myeloma Leuk.
14:e65–e68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson MR, Del Carpio-Jayo D, Lin P,
Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S,
Medeiros LJ and Bueso-Ramos CE: Primary plasma cell leukemia:
Morphologic, immunophenotypic, and cytogenetic features of 4 cases
treated with chemotherapy and stem cell transplantation. Ann Diagn
Pathol. 10:263–268. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song JY and Popplewell L: Circulating
reactive plasma cells in the setting of peripheral T-cell lymphoma
mimicking plasma cell leukemia. Blood. 126:11502015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Møller HE, Preiss BS, Pedersen P,
Kristensen IB, Hansen CT, Frederiksen M, Abildgaard N and Møller
MB: Clinicopathological features of plasmablastic multiple myeloma:
A population-based cohort. APMIS. 123:652–658. 2015. View Article : Google Scholar : PubMed/NCBI
|
